Clodronate

Clodronate used as an adjunct in the treatment of severe hypercalcaemia associated with malignancy.


Brands
Adult Dose
Dose: 0.035 mg/kg.min
Single Dose: 0.035 (0.035)
Frequency: 24 hourly
Route: IV Inf
Instructions: For 2 Hours per day, for not >10 days
Neonatal
Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group
Paedriatic
Dose: Safety not established
Single Dose:
Frequency:
Route:
Instructions:
Characteristics
. It is of Synthetic origin and belongs to Geminal Biphosphonate. It belongs to Osteoclast inhibitor pharmacological group on the basis of mechanism of action and also classified in Diphophonate pharmacological group.The Molecular Weight of Clodronate is 288.90. Its pKa is 1.0, 1.38,1.8, 6, 9.5.
Contraindications
Clodronate is contraindicated in conditions like Hypersensitivity,Renal insufficiency.
Effects
The severe or irreversible adverse effects of Clodronate, which give rise to further complications include Secondary hyperparathyroidism.Clodronate produces potentially life-threatening effects which include Acute Renal Failure. which are responsible for the discontinuation of Clodronate therapy.The signs and symptoms that are produced after the acute overdosage of Clodronate include Acute renal failure, Hypoglycemia.The symptomatic adverse reactions produced by Clodronate are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Vomiting, Diarrhea, GI upset, Hypocalcemia.
Indications
Clodronate is primarily indicated in conditions like Hypercalcaemia due to malignancy, Osteolytic bone metastases, Pagets disease.
Interactions
No data regarding the interactions of Clodronate was found.
Interfrence
Bone scintigraphy examinations
Risks
Drug should not be given to Paediatrics, Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Warnings
Adequate fluid intake must be maintained during clodronate treatment. This is particularly important when administering clodronate as intravenous infusion and in patients with hypercalcemia or renal failure. Intravenous administration of doses notably higher than those recommended may cause severe renal damage especially if the infusion rate is too high.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.